Girishanthy Krishnarajah, PhD

Senior Director Market Access and Strategy
Seqirus Vaccines Ltd.

Disclosure: Seqirus Vaccines Ltd. (Individual(s) Involved: Self): Employee, Shareholder

Presentation(s):

• 6 - MF59 ASSURANCE 2: A Real-world Study to Estimate the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-based Trivalent High-dose Among U.S. Older Adults During 2018-19 Influenza Season

  Oral Abstract